Drug Approval | May 04, 2022
Gland launches Bortezomib in the US market
Bortezomib for injection is used to treat certain types of cancer such as multiple myeloma and mantle cell lymphoma
Bortezomib for injection is used to treat certain types of cancer such as multiple myeloma and mantle cell lymphoma
CLNK is a biotechnology research and development company that utilizes umbilical cord blood as the raw material to develop innovative, allogeneic, off-the-shelf, cell based therapeutic products
Nuvaxovid is the first protein-based Covid-19 vaccine authorized for use in Switzerland
New Covid-19 Medriva Rapid Antigen Test kits with very high- sensitivity now available in Australia
Ind-Ra expects FY22 IPM to have witnessed 15% YoY sales growth, higher than the 8%-10% observed over the past five years, aided by the base effect
With this move, government hospitals across India can now access the geko device to prevent life-threatening blood clots, and address complications related to swelling following orthopaedic surgery and the healing of chronic wounds (leg ulcers)
The company’s differentiated value proposition comes during a time of unprecedented disruption in the life science supply chain
Recommendation based on Phase III PROVENT trial showing a significant reduction in the risk of developing symptomatic COVID-19, with protection lasting at least six months
Price was the key driver for the period
Meteoric Biopharmaceuticals have made rapid strides in the development of enzymes, probiotics and veterinary health products. It is seeking opportunities to scale up its growth backed by cutting edge R&D. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals spoke to Thomas C Thottathil on the way forward
Subscribe To Our Newsletter & Stay Updated
